Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This is a 8-week double-blind placebo controlled parallel group study of the efficacy of
varenicline (Chantix) for smoking cessation in schizophrenic patients, and its effect on
cognitive function in patients with schizophrenia.At some sits evaluation of smoking measures
is extended to 12 weeks. Correlations will be made with biological predictors of efficacy: a)
measures of nicotinic receptors in lymphocytes b) DNMT1 and GAD67 mRNA in lymphocytes.
Subjects will be current cigarette smokers or history of regular smokers.